Vir reports Week 96 SOLSTICE data, ECLIPSE program fully enrolled, VIR-5500 expansion underway
Second-quarter update details 88% viral suppression in hepatitis delta trial, Astellas collaboration progress, and $1.0 billion cash position.
Vir Biotechnology reported second-quarter 2026 results on August 5, 2026, alongside a series of pipeline updates. The company completed enrollment in the Phase 3 ECLIPSE 2 trial, evaluating a switch from bulevirtide to elebsiran and tobevibart in patients who had not achieved viral suppression on bulevirtide, meaning the entire ECLIPSE registrational program is now fully enrolled.1 Topline data from Phase 3 ECLIPSE 1 are expected in the fourth quarter of 2026, with ECLIPSE 2 and ECLIPSE 3 topline data expected in the first quarter of 2027.1
At the EASL Congress in May 2026, Vir presented complete Week 96 Phase 2 SOLSTICE data. In the intent-to-treat analysis, 88% (28/32) of participants on the combination of elebsiran and tobevibart achieved undetectable HDV RNA, compared with 53% (17/32) on antibody monotherapy.1 In a last observation carried forward analysis, the combination reached HDV RNA target not detected in 97% (31/32) of participants.1 The company said the combination continued to be generally well tolerated, with treatment-emergent adverse events generally mild to moderate and transient, and no treatment-related serious adverse events or discontinuations.1
In oncology, Vir closed its global strategic collaboration with Astellas to advance VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager for prostate cancer, and the companies rapidly worked together on Phase 1 trial design.1 The company initiated additional Phase 1 dose-expansion cohorts for VIR-5500 at Q3W 800/2000/3500 µg/kg step-up dosing, dosing first patients in three monotherapy cohorts across different mCRPC populations and one combination cohort with enzalutamide.1 Two more expansion cohorts, combining VIR-5500 with docetaxel or darolutamide, are anticipated, along with pivotal Phase 3 trials in 2027.1 Updated Phase 1 dose-escalation data for VIR-5818, a HER2-targeted TCE, are expected in the second half of 2026.1
As of June 30, 2026, Vir held approximately $1.01 billion in cash, cash equivalents and investments, an increase of about $198.5 million during the quarter.1 The increase reflected a $240.0 million upfront payment and $75 million equity investment from Astellas, offset by a $48.0 million pass-through payment to Sanofi.1 The company said it expects this cash position to fund operations into the second half of 2028.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.